Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z, Asaduzzaman M, Kumar U, Masrour N, Jugov R, Coombes RC, Shousha S, Hu Y, Lam EW, Yagüe E.
Mahmud Z, et al.
Biochem Pharmacol. 2019 May;163:391-403. doi: 10.1016/j.bcp.2019.03.009. Epub 2019 Mar 9.
Biochem Pharmacol. 2019.
PMID: 30862505
Free article.